DCAT Week, geared toward the business of pharmaceutical development and manufacturing, brings together thousands of senior industry executives for high-level meetings, strategy sessions, education programs and networking opportunities. Organized by the Drug, Chemical & Associated Technologies Association (DCAT), the event will take place in New York City from March 19-22, 2018.
DCAT is a not-for-profit, member-supported, global business development association with 400+ corporate members that includes innovator and generic drug companies and suppliers of ingredients, development and manufacturing services, and related technologies.
Innovation drives the pharmaceutical industry, so how is product innovation impacting manufacturing and supply, sourcing and procurement, and the supply lines of emerging pharma companies, which are an important source of new product development? DCAT Week ’18 will feature several education programs that will answer those questions.
New to DCAT Week, the Executive Insights: Manufacturing and Supply program will feature on-stage interviews with leading pharmaceutical executives who will share insights on the key drivers influencing pharmaceutical manufacturing and supply. These include how technology and product mix are impacting demand and supply, global manufacturing competitiveness, key issues influencing make-versus-buy decisions and specialized technologies such as continuous manufacturing.
Innovation in Sourcing and Procurement will offer best practices and lessons learned from leading executives in sourcing, procurement and supply management on how to drive value and performance in the pharmaceutical customer-supplier relationship. Topics include: advanced sourcing in new product development; innovative approaches in project management and supplier metrics to successfully move manufacturing of a molecule from in-house to external production; and best practices in collaborative supply-chain planning.
Emerging Pharma: Strategies for Optimizing Manufacturing and Supply will examine how emerging pharma companies can develop and implement the optimal manufacturing strategy for their drug candidates. The program will provide: insights on how drug pricing and the payer/reimbursement environment are impacting manufacturing decisions; best practices for the selection and management of CDMOs or CMOs; and manufacturing considerations in the due-diligence process when partnering with larger pharmaceutical companies in licensing deals, product acquisitions or full company acquisitions.
Further information on these programs and the other DCAT Week ’18 education programs may be found here: https://www.dcatweek.org.